125 related articles for article (PubMed ID: 9788573)
1. Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration.
Hassan M; Hassan Z; Nilsson C; Rehim MA; Kumlien S; Elfsson B; Kållberg N
Cancer Chemother Pharmacol; 1998; 42(6):471-8. PubMed ID: 9788573
[TBL] [Abstract][Full Text] [Related]
2. Development and characterization of an organic solvent free, proliposomal formulation of Busulfan using quality by design approach.
Chobisa D; Patel K; Monpara J; Patel M; Vavia P
Int J Pharm; 2018 Jan; 535(1-2):360-370. PubMed ID: 29126906
[TBL] [Abstract][Full Text] [Related]
3. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy.
Bhagwatwar HP; Phadungpojna S; Chow DS; Andersson BS
Cancer Chemother Pharmacol; 1996; 37(5):401-8. PubMed ID: 8599861
[TBL] [Abstract][Full Text] [Related]
4. Exposure equivalence between IV (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients.
Léger F; Nguyen L; Puozzo C
Eur J Clin Pharmacol; 2009 Sep; 65(9):903-11. PubMed ID: 19424688
[TBL] [Abstract][Full Text] [Related]
5. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan.
Vaughan WP; Carey D; Perry S; Westfall AO; Salzman DE
Biol Blood Marrow Transplant; 2002; 8(11):619-24. PubMed ID: 12463481
[TBL] [Abstract][Full Text] [Related]
6. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
Nguyen L; Leger F; Lennon S; Puozzo C
Cancer Chemother Pharmacol; 2006 Jan; 57(2):191-8. PubMed ID: 16133536
[TBL] [Abstract][Full Text] [Related]
7. Disposition of treosulfan and its active monoepoxide in a bone marrow, liver, lungs, brain, and muscle: Studies in a rat model with clinical relevance.
Romański M; Kasprzyk A; Walczak M; Ziółkowska A; Główka F
Eur J Pharm Sci; 2017 Nov; 109():616-623. PubMed ID: 28916482
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274
[TBL] [Abstract][Full Text] [Related]
9. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties.
Krishna R; Webb MS; St Onge G; Mayer LD
J Pharmacol Exp Ther; 2001 Sep; 298(3):1206-12. PubMed ID: 11504822
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients.
Le Gall JB; Milone MC; Waxman IM; Shaw LM; Harrison L; Duffy D; van de Ven C; Militano O; Geyer MB; Morris E; Bhatia M; Satwani P; George D; Garvin JH; Bradley MB; Schwartz J; Baxter-Lowe LA; Cairo MS
Bone Marrow Transplant; 2013 Jan; 48(1):19-25. PubMed ID: 22684047
[TBL] [Abstract][Full Text] [Related]
11. New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation.
Gaziev J; Isgrò A; Mozzi AF; Petain A; Nguyen L; Ialongo C; Dinallo V; Sodani P; Marziali M; Andreani M; Testi M; Paciaroni K; Gallucci C; De Angelis G; Alfieri C; Ribersani M; Lucarelli G
Pediatr Blood Cancer; 2015 Apr; 62(4):680-6. PubMed ID: 25557687
[TBL] [Abstract][Full Text] [Related]
12. Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring.
Nath CE; Shaw PJ
Curr Clin Pharmacol; 2007 Jan; 2(1):75-91. PubMed ID: 18690856
[TBL] [Abstract][Full Text] [Related]
13. Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?
Clemmons AB; Evans S; DeRemer DL; Awan FT
J Oncol Pharm Pract; 2015 Dec; 21(6):425-32. PubMed ID: 24986792
[TBL] [Abstract][Full Text] [Related]
14. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
[TBL] [Abstract][Full Text] [Related]
15. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
Vassal G; Michel G; Espérou H; Gentet JC; Valteau-Couanet D; Doz F; Mechinaud F; Galambrun C; Neven B; Zouabi H; Nguyen L; Puozzo C
Cancer Chemother Pharmacol; 2008 Jan; 61(1):113-23. PubMed ID: 17393167
[TBL] [Abstract][Full Text] [Related]
16. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and tissue distribution of d-alpha-tocopheryl succinate formulations following intravenous administration in the rat.
Teng XW; Davies NM; Fukuda C; Good RL; Fariss MW
Biopharm Drug Dispos; 2005 Jul; 26(5):195-203. PubMed ID: 15900617
[TBL] [Abstract][Full Text] [Related]
18. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results.
Michel G; Valteau-Couanet D; Gentet JC; Esperou H; Socié G; Méchinaud F; Doz F; Neven B; Bertrand Y; Galambrun C; Demeocq F; Yakouben K; Bordigoni P; Frappaz D; Nguyen L; Vassal G
Pediatr Blood Cancer; 2012 Jan; 58(1):90-7. PubMed ID: 21254374
[TBL] [Abstract][Full Text] [Related]
19. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
Nguyen L; Fuller D; Lennon S; Leger F; Puozzo C
Bone Marrow Transplant; 2004 May; 33(10):979-87. PubMed ID: 15064687
[TBL] [Abstract][Full Text] [Related]
20. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination.
Almog S; Kurnik D; Shimoni A; Loebstein R; Hassoun E; Gopher A; Halkin H; Nagler A
Biol Blood Marrow Transplant; 2011 Jan; 17(1):117-23. PubMed ID: 20601034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
